HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

David M Margolis Selected Research

HIV Infections (HIV Infection)

1/2022Stable Latent HIV Infection and Low-level Viremia Despite Treatment With the Broadly Neutralizing Antibody VRC07-523LS and the Latency Reversal Agent Vorinostat.
1/2021Multi-omics analyses reveal that HIV-1 alters CD4+ T cell immunometabolism to fuel virus replication.
1/2021Epigenomic characterization of latent HIV infection identifies latency regulating transcription factors.
11/2020Impact of Biological Sex on Immune Activation and Frequency of the Latent HIV Reservoir During Suppressive Antiretroviral Therapy.
11/2020Efficacy, pharmacokinetics and neurocognitive performance of dual, NRTI-sparing antiretroviral therapy in acute HIV-infection.
10/2020Evaluation of EED Inhibitors as a Class of PRC2-Targeted Small Molecules for HIV Latency Reversal.
1/2020Curing HIV: Seeking to Target and Clear Persistent Infection.
1/2020Systemic HIV and SIV latency reversal via non-canonical NF-κB signalling in vivo.
1/2020Assessing the impact of AGS-004, a dendritic cell-based immunotherapy, and vorinostat on persistent HIV-1 Infection.
12/2019HIV-Specific T Cell Responses Are Highly Stable on Antiretroviral Therapy.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


David M Margolis Research Topics

Disease

46Infections
10/2021 - 05/2004
45HIV Infections (HIV Infection)
01/2022 - 05/2004
21Viremia
01/2022 - 10/2004
7Persistent Infection
01/2022 - 03/2009
6Acquired Immunodeficiency Syndrome (AIDS)
01/2018 - 05/2002
5Latent Infection
08/2017 - 08/2005
4COVID-19
10/2021 - 01/2020
4Shock
03/2021 - 02/2014
2Inflammation (Inflammations)
01/2019 - 03/2015
1Lung Diseases (Lung Disease)
12/2020
1Body Weight (Weight, Body)
10/2020
1Neoplasms (Cancer)
10/2018
1Virus Diseases (Viral Diseases)
11/2016
1Myeloid Sarcoma (Chloroma)
09/2014
1Neuroblastoma
09/2014
1Disease Progression
03/2014
1Pain (Aches)
07/2012
1Mucositis
07/2012
1Human Influenza (Influenza)
07/2009
1Dyslipidemias (Dyslipidemia)
02/2008
1Insulin Resistance
02/2008
1Long Term Adverse Effects
08/2006
1Drug-Related Side Effects and Adverse Reactions
12/2004
1Vomiting
12/2004
1Exanthema (Rash)
12/2004
1Diarrhea
12/2004
1Headache (Headaches)
12/2004
1Abdominal Pain (Pain, Abdominal)
12/2004

Drug/Important Bio-Agent (IBA)

15RNA (Ribonucleic Acid)IBA
01/2022 - 06/2008
12Histone Deacetylase InhibitorsIBA
08/2017 - 05/2004
7DNA (Deoxyribonucleic Acid)IBA
01/2022 - 12/2006
6AntibodiesIBA
02/2021 - 07/2009
5Antiviral Agents (Antivirals)IBA
10/2020 - 06/2008
4VorinostatFDA Link
01/2022 - 11/2015
4Histone Deacetylases (Histone Deacetylase)IBA
01/2014 - 10/2007
4Valproic Acid (Depakote)FDA LinkGeneric
02/2010 - 08/2005
3Neutralizing AntibodiesIBA
10/2021 - 01/2021
3Viral AntigensIBA
09/2017 - 01/2016
3Raltegravir PotassiumFDA Link
03/2012 - 02/2010
3Pharmaceutical PreparationsIBA
05/2009 - 10/2007
3Atazanavir Sulfate (Reyataz)FDA Link
02/2008 - 12/2004
2N,N'- (2,2'- (hexa- 2,4- diyne- 1,6- diylbis(oxy))bis(2,3- dihydro- 1H- indene- 2,1- diyl))bis(1- (2- cyclohexyl- 2- (2- (methylamino)propanamido)acetyl)pyrrolidine- 2- carboxamide)IBA
02/2021 - 10/2020
2AntigensIBA
02/2021 - 10/2011
2Angiotensin-Converting Enzyme 2IBA
12/2020 - 01/2020
2Rifaximin (L 105)FDA Link
01/2019 - 03/2015
2Anti-Bacterial Agents (Antibiotics)IBA
01/2019 - 03/2015
2Histones (Histone)IBA
01/2018 - 10/2004
2EnzymesIBA
01/2018 - 08/2005
2Enfuvirtide (Fuzeon)FDA Link
02/2010 - 08/2005
2Protease Inhibitors (Protease Inhibitor)IBA
02/2008 - 12/2004
2Ritonavir (Norvir)FDA Link
02/2008 - 08/2006
1Broadly Neutralizing AntibodiesIBA
01/2022
1Transcription Factors (Transcription Factor)IBA
01/2021
1Mitochondrial Proteins (Mitochondrial Protein)IBA
01/2021
1InterferonsIBA
11/2020
1ChromatinIBA
10/2020
1LuciferasesIBA
01/2020
1Lysine (L-Lysine)FDA Link
01/2018
1Fatty Acids (Saturated Fatty Acids)IBA
01/2018
1HIV AntibodiesIBA
01/2017
1efavirenz (Sustiva)FDA Link
11/2016
1Tenofovir (Viread)FDA Link
11/2016
1Emtricitabine (Emtriva)FDA Link
11/2016
1pifithrinIBA
11/2016
1ProteomeIBA
11/2015
1CD4 Antigens (CD4 Antigen)IBA
10/2015
1LipopolysaccharidesIBA
03/2015
1HLA-B57 antigenIBA
03/2014
1Proteins (Proteins, Gene)FDA Link
02/2014
1prostratinIBA
02/2014
1BryostatinsIBA
02/2014
1Protein Kinase CIBA
02/2014
1Biological ProductsIBA
05/2013
1NucleosidesIBA
04/2011
1Reverse Transcriptase InhibitorsIBA
04/2011
1AcetylesteraseIBA
01/2011
1Integrase InhibitorsIBA
08/2009
1RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA
08/2009
1LipidsIBA
12/2008
1TAK 779IBA
06/2008
1hexamethylene bisacetamide (HMBA)IBA
04/2008
1Phosphotransferases (Kinase)IBA
04/2008
1Triglycerides (Triacylglycerol)IBA
02/2008
1Insulin (Novolin)FDA Link
02/2008
1amdoxovirIBA
10/2007
1Mycophenolic Acid (Cellcept)FDA LinkGeneric
10/2007
1formal glycol (dioxolane)IBA
10/2007
1Cyclosporine (Ciclosporin)FDA LinkGeneric
12/2006
1Histone Deacetylase 1IBA
08/2005
1Uridine Diphosphate (UDP)IBA
12/2004

Therapy/Procedure

50Therapeutics
01/2022 - 05/2002
22Art Therapy
11/2020 - 12/2006
7Immunotherapy
01/2022 - 05/2016
5Highly Active Antiretroviral Therapy (HAART)
02/2017 - 12/2004
1Hematopoietic Stem Cell Transplantation
10/2018
1Secondary Prevention
09/2014
1Investigational Therapies (Experimental Therapy)
03/2014
1Phototherapy (Light Therapy)
07/2012
1Radiotherapy
07/2012
1Drug Therapy (Chemotherapy)
07/2012